Market Overview

Mylan Pharma Wins Final FDA Approval for ANDA for Phenytoin Chewable Tablets, 50 mg

Related MYL
Benzinga's Top Downgrades
US Stock Futures Edge Higher Ahead Of Productivity Data
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)
Related PFE
Markets Continue To Rally Ahead Of Yellen's Speech At Jackson Hole
Pfizer Could Revive AstraZeneca Bid As Early As Tuesday
Treasury Develolping Options to Curb Inversions (Fox Business)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of Pfizer's Dilantin® Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Posted-In: News FDA

 

Related Articles (MYL + PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional